Tonix Pharmaceuticals Holding Corp. [NASDAQ: TNXP] jumped around 0.01 points on Monday, while shares priced at $0.62 at the close of the session, up 1.67%. The company report on September 27, 2021 that Tonix Pharmaceuticals Announces Oral Presentation at the American College of Rheumatology Convergence 2021.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announces the acceptance and details of an oral presentation at the American College of Rheumatology (ACR) Convergence 2021. The ACR Convergence 2021 is being held virtually November 5-9, 2021. A copy of the presentation will be made available under the IR Events tab of the Investors section of the Tonix website following the presentation at www.tonixpharma.com. The oral presentation details are as follows:.
Tonix Pharmaceuticals Holding Corp. stock is now -8.68% down from its year-to-date (YTD) trading value. TNXP Stock saw the intraday high of $0.635 and lowest of $0.601 per share. The company’s 52-week high price is 2.12, which means current price is +6.90% above from all time high which was touched on 02/11/21.
Compared to the average trading volume of 11.74M shares, TNXP reached a trading volume of 14268591 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Tonix Pharmaceuticals Holding Corp. [TNXP]?
ROTH Capital have made an estimate for Tonix Pharmaceuticals Holding Corp. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 18, 2019. The new note on the price target was released on August 18, 2017, representing the official price target for Tonix Pharmaceuticals Holding Corp. stock. On February 17, 2016, analysts decreased their price target for TNXP shares from 18 to 10.
The Average True Range (ATR) for Tonix Pharmaceuticals Holding Corp. is set at 0.04 The Price to Book ratio for the last quarter was 1.14, with the Price to Cash per share for the same quarter was set at 0.45.
How has TNXP stock performed recently?
Tonix Pharmaceuticals Holding Corp. [TNXP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.65. With this latest performance, TNXP shares dropped by -12.48% in over the last four-week period, additionally sinking by -49.06% over the last 6 months – not to mention a drop of -27.31% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TNXP stock in for the last two-week period is set at 39.60, with the RSI for the last a single of trading hit 43.25, and the three-weeks RSI is set at 39.18 for Tonix Pharmaceuticals Holding Corp. [TNXP]. The present Moving Average for the last 50 days of trading for this stock 0.7109, while it was recorded at 0.6114 for the last single week of trading, and 1.0079 for the last 200 days.
Tonix Pharmaceuticals Holding Corp. [TNXP]: Deeper insight into the fundamentals
Return on Total Capital for TNXP is now -102.32, given the latest momentum, and Return on Invested Capital for the company is -103.21. Return on Equity for this stock declined to -103.98, with Return on Assets sitting at -89.52. When it comes to the capital structure of this company, Tonix Pharmaceuticals Holding Corp. [TNXP] has a Total Debt to Total Equity ratio set at 1.50. Additionally, TNXP Total Debt to Total Capital is recorded at 1.47, with Total Debt to Total Assets ending up at 1.34. Long-Term Debt to Equity for the company is recorded at 0.82, with the Long-Term Debt to Total Capital now at 0.80.
Reflecting on the efficiency of the workforce at the company, Tonix Pharmaceuticals Holding Corp. [TNXP] managed to generate an average of -$2,968,412 per employee.Tonix Pharmaceuticals Holding Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 21.90 and a Current Ratio set at 21.90.
Insider trade positions for Tonix Pharmaceuticals Holding Corp. [TNXP]
There are presently around $46 million, or 21.60% of TNXP stock, in the hands of institutional investors. The top three institutional holders of TNXP stocks are: BLACKROCK INC. with ownership of 26,501,101, which is approximately 248.582% of the company’s market cap and around 0.07% of the total institutional ownership; VANGUARD GROUP INC, holding 15,766,539 shares of the stock with an approximate value of $9.71 million in TNXP stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $4.44 million in TNXP stock with ownership of nearly -14.793% of the company’s market capitalization.
Positions in Tonix Pharmaceuticals Holding Corp. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 53 institutional holders increased their position in Tonix Pharmaceuticals Holding Corp. [NASDAQ:TNXP] by around 38,227,232 shares. Additionally, 30 investors decreased positions by around 4,532,900 shares, while 22 investors held positions by with 31,557,249 shares. The mentioned changes placed institutional holdings at 74,317,381 shares, according to the latest SEC report filing. TNXP stock had 37 new institutional investments in for a total of 6,100,271 shares, while 18 institutional investors sold positions of 2,422,253 shares during the same period.